Veracyte, Inc. (FRA:12V)
Germany flag Germany · Delayed Price · Currency is EUR
40.40
+0.80 (2.02%)
Last updated: Dec 4, 2025, 8:07 AM CET

Veracyte Company Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.

Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte, Inc.
Country United States
Founded 2006
Industry In Vitro and In Vivo Diagnostic Substances
Employees 824
CEO Marc Stapley

Contact Details

Address:
6000 Shoreline Court
South San Francisco, Delaware 94080
United States
Phone 650 243 6300
Website veracyte.com

Stock Details

Ticker Symbol 12V
Exchange Frankfurt Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2835

Key Executives

Name Position
Marc Stapley Chief Executive Officer
Rebecca Chambers Chief Financial Officer
Keith Gligorich Chief Operating Officer